<SEC-DOCUMENT>0001213900-26-025920.txt : 20260311
<SEC-HEADER>0001213900-26-025920.hdr.sgml : 20260311
<ACCEPTANCE-DATETIME>20260311064018
ACCESSION NUMBER:		0001213900-26-025920
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20260311
DATE AS OF CHANGE:		20260311

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bluejay Diagnostics, Inc.
		CENTRAL INDEX KEY:			0001704287
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				473552922
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-93056
		FILM NUMBER:		26741495

	BUSINESS ADDRESS:	
		STREET 1:		360 MASSACHUSETTS AVENUE, SUITE 203
		CITY:			ACTON
		STATE:			MA
		ZIP:			01720
		BUSINESS PHONE:		(978) 631-0152

	MAIL ADDRESS:	
		STREET 1:		360 MASSACHUSETTS AVENUE, SUITE 203
		CITY:			ACTON
		STATE:			MA
		ZIP:			01720

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NORTHSTRIVE FUND II LP
		CENTRAL INDEX KEY:			0002099270
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D

	BUSINESS ADDRESS:	
		STREET 1:		120 NEWPORT CENTER DR
		STREET 2:		STE 250
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			926660
		BUSINESS PHONE:		9498757003

	MAIL ADDRESS:	
		STREET 1:		120 NEWPORT CENTER DR
		STREET 2:		STE 250
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			926660
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: NORTHSTRIVE FUND II LP -->
          <cik>0002099270</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock, par value $0.0001 per share</securitiesClassTitle>
      <dateOfEvent>03/11/2026</dateOfEvent>
      <previouslyFiledFlag>true</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001704287</issuerCIK>
        <issuerCUSIP>095633608</issuerCUSIP>
        <issuerName>Bluejay Diagnostics, Inc.</issuerName>
        <address>
          <com:street1>360 Massachusetts Avenue</com:street1>
          <com:street2>Suite 203</com:street2>
          <com:city>Acton</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>01720</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Ross. D. Carmel, Esq.</personName>
          <personPhoneNum>(212) 930-9700</personPhoneNum>
          <personAddress>
            <com:street1>1185 Avenue of the Americas</com:street1>
            <com:street2>26th Floor</com:street2>
            <com:city>New York</com:city>
            <com:stateOrCountry>NY</com:stateOrCountry>
            <com:zipCode>10036</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0002099270</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Northstrive Fund II LP</reportingPersonName>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>11000.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>11000.00</sharedDispositivePower>
        <aggregateAmountOwned>11000.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>1.13</percentOfClass>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
        <commentContent>Braeden Lichti is, as of the date of this Schedule 13D, the Manager of Northstrive Fund II LP. Percentage ownership is calculated based on 11,000 shares of Bluejay Diagnostics, Inc. ("Issuer") beneficially owned by Northstrive Fund II LP, out of 972,000 shares of the Issuer's issued and outstanding shares of common stock, par value $0.0001 per share ("Common Stock") as reported in the Issuer's press release, filed as an exhibit to the Issuer's Current Report on Form 8-K with the U.S. Securities and Exchange Commission ("SEC") on March 6, 2026.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001982476</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Braeden Lichti</reportingPersonName>
        <fundType>PF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>Z4</citizenshipOrOrganization>
        <soleVotingPower>24500.00</soleVotingPower>
        <sharedVotingPower>11000.00</sharedVotingPower>
        <soleDispositivePower>24500.00</soleDispositivePower>
        <sharedDispositivePower>11000.00</sharedDispositivePower>
        <aggregateAmountOwned>35500.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>3.65</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <commentContent>Braeden Lichti is, as of the date of this Schedule 13D, the Manager of Northstrive Fund II LP. Percentage ownership is calculated based on 35,500 shares of the Issuer beneficially owned by Braeden Lichti, out of 972,000 shares of the Issuer's issued and outstanding shares of Common Stock, based on the Issuer's press release, filed as an exhibit to the Issuer's Current Report on Form 8-K with the SEC on March 6, 2026.</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock, par value $0.0001 per share</securityTitle>
        <issuerName>Bluejay Diagnostics, Inc.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>360 Massachusetts Avenue</com:street1>
          <com:street2>Suite 203</com:street2>
          <com:city>Acton</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>01720</com:zipCode>
        </issuerPrincipalAddress>
        <commentText>Northstrive Fund (as defined below) and Mr. Braeden Lichti previously filed a Schedule 13G on February 5, 2026 (the "Schedule 13G"). This Statement on Schedule 13D relates to the Common Stock of the Issuer and amends the Schedule 13G. The principal executive offices of the Issuer are located at 360 Massachusetts Avenue, Suite 203, Acton, MA 01720.</commentText>
      </item1>
      <item2>
        <filingPersonName>This Schedule 13D is filed jointly by Northstrive Fund II LP ("Northstrive Fund") and Mr. Braeden Lichti (together with Northstrive Fund, the "Reporting Persons"). The shares of Common Stock are held jointly by the Reporting Persons. Mr. Lichti is, as of the date of this Schedule 13D, the Manager of Northstrive Fund, and he has voting and investment power of those shares of Common Stock held by Northstrive Fund.</filingPersonName>
        <principalBusinessAddress>The address of each of the Reporting Persons is 120 Newport Center Drive, Newport Beach, CA 92660.</principalBusinessAddress>
        <principalJob>Northstrive Fund is principally engaged in the business of investments into private and public securities. Mr. Lichti is principally engaged as the Chief Executive Officer of Northstrive Companies Inc., a California based management, advisory and investment company.</principalJob>
        <hasBeenConvicted>Neither of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors) or been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.</hasBeenConvicted>
        <convictionDescription>None of the Reporting Persons have, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.</convictionDescription>
        <citizenship>Northstrive Fund is a Delaware limited partnership. Mr. Lichti is a citizen of Canada.</citizenship>
      </item2>
      <item3>
        <fundsSource>The information set forth in Item 4 is incorporated by reference herein. Northstrive Fund used working capital as the source of funds for its purchase of the Common Stock. Mr. Lichti used personal funds to purchase his shares of Common Stock.</fundsSource>
      </item3>
      <item4>
        <transactionPurpose>As of March 10, 2026, Mr. Lichti and Northstrive Fund II LP beneficially owned 35,500 and 11,000 shares of Common Stock, respectively, representing 3.65% and 1.13% of the Issuer's issued and outstanding Common Stock. This percentage was calculated based on 972,000 shares of the Issuer's issued and outstanding shares of Common Stock, based on the Issuer's press release, filed as an exhibit to the Issuer's Current Report on Form 8-K with the SEC on March 6, 2026. This Schedule 13D is being filed to disclose Northstrive's Fund letter to the Board of Directors of the Issuer (the "Board") dated March 11, 2026 (the "Board Letter"). The Board Letter includes, among other things, Northstrive Fund's recommendations to the Board to review a potential biotechnology acquisition opportunity that Northstrive Fund has identified, in order to strengthen the Issuer's clinical pipeline and accelerate shareholder value creation, in Northstrive Fund's view. Northstrive Fund has requested to meet with the Board in the Board Letter. The Board Letter is filed herein as Exhibit A. As the Board Letter indicates an intent by the Reporting Persons with a purpose or effect to potentially change or influence control of the Issuer, the Reporting Persons have deemed it appropriate to amend the Schedule 13G by filing this Schedule 13D. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors, including, without limitation, the Issuer's financial position and investment strategy, the price levels of the Common Stock, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate, which may include liquidation or further accumulation of shares. In addition, the Reporting Persons may, at any time and from time to time, (i) review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto and (ii) propose or consider one or more of the actions described in subparagraphs (a) - (j) of Item 4 of Schedule 13D.</transactionPurpose>
      </item4>
      <item5>
        <percentageOfClassSecurities>See the information contained on the cover pages of this Schedule 13D, which is incorporated herein by reference. The percentage of Common Stock reported as beneficially owned by each Reporting Person is based on 972,000 shares of the Issuer's issued and outstanding shares of Common Stock, based on the Issuer's press release, filed as an exhibit to the Issuer's Current Report on Form 8-K with the SEC on March 6, 2026.</percentageOfClassSecurities>
        <numberOfShares>Sole power to vote or to direct the vote: Northstrive Fund II LP: 0 shares Braeden Lichti: 24,500 shares
Shared power to vote or to direct the vote: Northstrive Fund II LP: 11,000 shares Braeden Lichti: 11,000 shares
Sole power to dispose or to direct the disposition of: Northstrive Fund II LP: 0 shares Braeden Lichti: 24,500 shares
Shared power to dispose or to direct the disposition: Northstrive Fund II LP: 11,000 shares Braeden Lichti: 11,000 shares</numberOfShares>
        <transactionDesc>The information set forth in Item 3 above is incorporated herein by reference.</transactionDesc>
        <listOfShareholders>Not applicable.</listOfShareholders>
        <date5PercentOwnership>2/20/2026</date5PercentOwnership>
      </item5>
      <item6>
        <contractDescription>The information in Items 3 and 4 is incorporated herein by reference.</contractDescription>
      </item6>
      <item7>
        <filedExhibits>Exhibit A Letter to the Board of Directors of Issuer
Exhibit B Transactions completed by Reporting Persons in the Common Stock</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Northstrive Fund II LP</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Braeden Lichti</signature>
          <title>Braeden Lichti/Manager</title>
          <date>03/11/2026</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Braeden Lichti</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Braeden Lichti</signature>
          <title>Braeden Lichti</title>
          <date>03/11/2026</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.A
<SEQUENCE>2
<FILENAME>ea028037501ex-a.htm
<DESCRIPTION>LETTER TO THE BOARD OF DIRECTORS OF ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ea028037501_ex-aimg1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Northstrive Fund II LP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">120 Newport Center Drive, Newport Beach, CA 92660</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bluejay Diagnostics, Inc.<BR>
360 Massachusetts Avenue, Suite 203<BR>
Acton, MA 01720</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">March 11, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Members of the Board of Directors and Fellow Shareholders,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NorthStrive Fund II LP (&ldquo;NorthStrive
Fund&rdquo;, &ldquo;we&rdquo;, &ldquo;our&rdquo; or &ldquo;us&rdquo;), a subsidiary of NorthStrive Companies Inc., headquartered in
Newport Beach, California, is a significant shareholder of Bluejay Diagnostics, Inc. (the &ldquo;Company&rdquo; or
&ldquo;Bluejay&rdquo;), as disclosed in our Schedule 13G filed with the U.S. Securities and Exchange Commission on February 5,
2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe, based on the Company&rsquo;s current
market capitalization and clinical trajectory, Bluejay is in a unique position today to capitalize and reward shareholders with an appealing
biotechnology acquisition we have identified. We would like to recommend that the Company&rsquo;s Board of Directors (&ldquo;Board&rdquo;)
review this turnkey acquisition and financing opportunity that we believe could strengthen the Company&rsquo;s clinical pipeline and accelerate
shareholder value creation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While we support the Company&rsquo;s continued
progress in advancing its current core program, SYMON&trade; II, we believe Bluejay has an immediate acquisition opportunity to further
enhance its pipeline, and create shareholder value by acquiring a Phase 1 ready asset potentially capable of introducing near-term clinical
catalysts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Specifically, we believe the Company should evaluate
a Phase-1-ready therapeutic opportunity outlined below, which we believe represents a compelling and ready-to-execute transaction capable
of introducing new value-inflection points for shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Key Considerations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In evaluating opportunities to benefit shareholders
and strengthen the Company&rsquo;s clinical pipeline, we believe the Board should consider several strategic priorities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pipeline Expansion</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Evaluate opportunities to add a Phase-1-ready or clinical-stage
program with a differentiated mechanism of action, clear competitive advantage, and compelling risk-adjusted upside.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Prioritize assets targeting well-defined patient populations
that allow for efficient clinical trial enrollment and meaningful commercial opportunity.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">We believe expanding the pipeline would reduce single-asset
risk while introducing additional clinical catalysts capable of enhancing the Company&rsquo;s long-term shareholder value.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Near-Term Clinical Catalysts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Prioritize programs capable of generating meaningful clinical
milestones within the next 12&ndash;24 months, with modest capital requirements and efficient clinical development.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Focus on assets with streamlined trial designs and accessible
patient populations, allowing for efficient enrollment and timely data readouts.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Regular clinical catalysts can significantly enhance investor
visibility and valuation for emerging biotechnology companies.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shareholder Value Creation &amp; Investor Awareness</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Expanding the clinical pipeline may increase investor visibility
and attract new institutional shareholders.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">A broader pipeline with multiple development programs can
enhance market awareness and support stronger long-term market valuation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Companies with diversified clinical programs and regular
catalysts often experience greater investor engagement and improved shareholder value over time.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Potential Strategic Opportunity in Refractory Chronic Cough
(&ldquo;RCC&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe the Board may benefit from reviewing
and ultimately acquiring a Phase-1-ready therapeutic asset targeting refractory chronic cough (&ldquo;RCC&rdquo;), a debilitating condition
affecting millions of patients globally and representing a significant unmet medical need. According to our research, the global treatment
market for refractory chronic cough is estimated to exceed $10 billion annually and is expected to grow as new therapies are developed.
[<I>Source 1, Source 2</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The program is centered around a proprietary small-molecule
inhibitor of fatty acid amide hydrolase (FAAH) designed to increase levels of the endogenous signaling molecule anandamide, which may
help desensitize hyperactive sensory neurons responsible for triggering the cough reflex.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Key attributes of the program include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Phase-1-ready asset with IND-enabling studies completed</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Differentiated mechanism through peripheral FAAH inhibition
designed to avoid central nervous system exposure</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Strong biological rationale linking neuronal hypersensitivity
to chronic cough</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Preclinical proof of concept demonstrated in validated cough
models</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Multiple upcoming clinical milestones, including first-in-human
dosing and Phase 1 safety and pharmacokinetic readouts</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Potential expansion into additional indications, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Neuropathic pain</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Hyperactive bladder</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Migraines</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe a program with this profile could introduce
multiple near-term value inflection points while complementing the Company&rsquo;s existing strategic direction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent M&amp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest from larger pharmaceutical companies
in the RCC space has increased in recent years as the biology has become better understood and the commercial opportunity more visible.
We believe the most notable recent transaction was <B>GSK&rsquo;s approximately $2.0 billion acquisition of BELLUS Health in 2023</B>,
driven by BELLUS&rsquo;s late-stage <B>P2X3 antagonist</B> program in RCC. [Source 1, Source 2]. We believe these developments underscore
both the scale of the opportunity and the willingness of larger players to acquire differentiated assets as clinical proof-of-concept
begins to emerge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Differentiation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Most advanced chronic cough programs have focused
on the <B>P2X3 receptor</B>, a pathway associated with antitussive efficacy but commonly associated with <B>taste disturbance</B> as a
tolerability limitation. [Source 3] By contrast, the opportunity we are presenting is mechanistically distinct: a <B>peripherally selective
FAAH inhibitor</B> designed to increase <B>anandamide</B> levels and reduce hypersensitivity in airway sensory neurons while being designed
to remain <B>outside the central nervous system</B>. We believe this differentiated approach may reduce the risk of centrally mediated
side effects and may avoid the taste-related tolerability issues seen with P2X3 antagonists, while also creating potential for expansion
into additional neuronal hypersensitivity indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sources </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Source 1:</B> GSK &mdash; &ldquo;GSK completes
acquisition of BELLUS Health&rdquo; (June 28, 2023).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Source 2:</B> BioPharma Dive &mdash; &ldquo;GSK to buy Bellus Health and its chronic cough drug for $2B&rdquo; (Feb 2023).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Source 3:</B> CHEST journal &mdash; &ldquo;Benefit-Risk Profile of P2X3 Receptor Antagonists&hellip;&rdquo; (notes taste disturbance
as common adverse effect).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Parallel Financing Opportunity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Importantly, the Company has advised us that approximately
$5,000,000 in financing may be available through a public company financing structure, contingent upon the successful combination of the
asset within a public company platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This structure may allow the Company to advance
the proposed program while strengthening its balance sheet and reducing near-term financing risk for shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Conclusion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have completed preliminary due diligence on
this opportunity and believe it represents a novel and differentiated program with the potential to introduce meaningful clinical catalysts
and create substantial shareholder value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The asset is currently available for acquisition,
and financing is available. We would welcome the opportunity to provide the Company with our due diligence materials and facilitate direct
engagement with the program&rsquo;s representatives upon receipt of this letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Request for Board Review</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We respectfully encourage the Board to promptly
engage with us to review this opportunity, which we believe could meaningfully strengthen the Company&rsquo;s development pipeline and
accelerate shareholder value creation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please contact us at [***]. I will also make attempts to contact Mr.
Dey and other members of the Board directly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Northstrive Fund and Braeden Lichti hold no interest in or
arrangement with the acquisition target. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Respectfully,&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Braeden Lichti</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Braeden Lichti, Manager of NorthStrive Fund II LP</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About NorthStrive Fund II LP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">NorthStrive Fund II
LP is an investment vehicle and subsidiary of NorthStrive Companies Inc., headquartered in Newport Beach, California. NorthStrive
Fund focuses on public and private investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Disclaimer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The information in this
letter (&ldquo;Letter&rdquo;) &nbsp;&nbsp;is for informational purposes only and does not constitute an offer to purchase or sell any
security, nor does it constitute investment, legal, or financial advice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The information contained
herein is based on publicly available information relating to Bluejay Diagnostics, Inc. Except where otherwise indicated, the information
in this Letter speaks only as of the date hereof, and NorthStrive Fund II LP undertakes no obligation to update or revise any statements
contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Letter may
include forward-looking statements that reflect current views regarding future events, strategic alternatives, or potential
outcomes. Forward-looking statements are typically identified by words such as &ldquo;expect,&rdquo; &ldquo;intend,&rdquo;
&ldquo;plan,&rdquo; &ldquo;believe,&rdquo; &ldquo;project,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;will,&rdquo; &ldquo;may,&rdquo;
&ldquo;would,&rdquo; or similar expressions. These statements involve risks and uncertainties, many of which are beyond NorthStrive
Fund&rsquo;s control. Actual results may differ materially from those expressed or implied in such statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Any financial estimates
or projections included herein, including those contained in the financial model referenced in this Letter, are based on assumptions believed
to be reasonable but are inherently subject to uncertainty and may not reflect actual outcomes. Shareholders should conduct their own
independent analysis and reach their own conclusions regarding the matters discussed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">NorthStrive Fund II
LP currently beneficially owns securities of the Company. NorthStrive Fund reserves the right to increase or decrease its ownership
of Company securities at any time, including through purchases, sales, derivatives, or other transactions, subject to applicable
law. NorthStrive Fund also reserves the right to engage in discussions with the Board of Directors, management, shareholders, or
other parties regarding strategic alternatives or other matters relating to its investment in the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Although
NorthStrive Fund believes the information contained herein to be reliable, it makes no representation or warranty, express or
implied, as to the accuracy or completeness of the information and expressly disclaims any liability arising from reliance on such
information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.B
<SEQUENCE>3
<FILENAME>ea028037501ex-b.htm
<DESCRIPTION>TRANSACTIONS COMPLETED BY REPORTING PERSONS IN THE COMMON STOCK
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is a list of all transactions completed by each Reporting
Person in the Common Stock since the date of first purchase of the Common Stock, which were all completed through open market purchases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Northstrive Fund II LP</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-bottom: 0pt; font-weight: bold; padding-left: 0pt">Date</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Action</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Quantity</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Price</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Amount</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 53%; padding-bottom: 0pt; padding-left: 0pt">2/5/2026</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Buy</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5,000</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3.1357</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">15,678.50</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 0pt; padding-left: 0pt">2/2/2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Buy</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.6856</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">18,428.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; padding-left: 0pt">1/30/2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Buy</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.4299</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,429.90</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Braeden Lichti</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; font-weight: bold; vertical-align: bottom">Date</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Action</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Quantity</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Price</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Amount</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 53%; padding-bottom: 1.5pt; padding-left: 0pt">2/5/2026</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Buy</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">8,500</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3.1952</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">27,159.20</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">2/5/2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Buy</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.1066</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">18,639.60</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">2/5/2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Buy</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.0749</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">30,749.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ea028037501_ex-aimg1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028037501_ex-aimg1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  I ,X# 2(  A$! Q$!_\0
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MF>X%GIS2V\DARPC((*DGJ <8^M<9X/\ !^H^-;Z;3-/G@A$,?GOY[,$QD#@
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MJ0VJ$??EDP6./;@?\!->S?$WPA_PEOA22.! =1M,SVI[D@<I_P "''UQ7 ?
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75I44 -CC2) D:*B*,!5& *=110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
